Correlation Between Mineralys Therapeutics, and Adaptimmune Therapeutics
Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Adaptimmune Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Adaptimmune Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mineralys Therapeutics, Common and Adaptimmune Therapeutics Plc, you can compare the effects of market volatilities on Mineralys Therapeutics, and Adaptimmune Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Adaptimmune Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Adaptimmune Therapeutics.
Diversification Opportunities for Mineralys Therapeutics, and Adaptimmune Therapeutics
-0.46 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Mineralys and Adaptimmune is -0.46. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Adaptimmune Therapeutics Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adaptimmune Therapeutics and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Adaptimmune Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adaptimmune Therapeutics has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Adaptimmune Therapeutics go up and down completely randomly.
Pair Corralation between Mineralys Therapeutics, and Adaptimmune Therapeutics
Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to under-perform the Adaptimmune Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Mineralys Therapeutics, Common is 1.25 times less risky than Adaptimmune Therapeutics. The stock trades about -0.05 of its potential returns per unit of risk. The Adaptimmune Therapeutics Plc is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest 74.00 in Adaptimmune Therapeutics Plc on August 28, 2024 and sell it today you would lose (4.00) from holding Adaptimmune Therapeutics Plc or give up 5.41% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Mineralys Therapeutics, Common vs. Adaptimmune Therapeutics Plc
Performance |
| Timeline |
| Mineralys Therapeutics, |
| Adaptimmune Therapeutics |
Mineralys Therapeutics, and Adaptimmune Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Mineralys Therapeutics, and Adaptimmune Therapeutics
The main advantage of trading using opposite Mineralys Therapeutics, and Adaptimmune Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Adaptimmune Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will offset losses from the drop in Adaptimmune Therapeutics' long position.| Mineralys Therapeutics, vs. Eliem Therapeutics | Mineralys Therapeutics, vs. HCW Biologics | Mineralys Therapeutics, vs. Scpharmaceuticals | Mineralys Therapeutics, vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Complementary Tools
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |